Excellent post here.25 pps possible Since the 8k nothing

New Post Public Reply Private Reply Replies (0) Message Board
Pugilista
479

Excellent post here.25 pps possible
Since the 8k nothing have changed except a higher revenue as stated by a third party. Here are some tantalizing thoughts from a poster on another poster which was xyz1002.

art35 Member Level Sunday, 03/05/17 05:41:58 PM
Re: None
Post #
66382
of 90314 Go
Here another post from same poster--

Hold till at least $0.25. Here is why? It will get there much sooner than anyone can imagine.

1) Ignore the OS. The float is very small. No one knows the float. The last reported float was like under 100M. From my 18 yrs of investment, if I had to take a wild guess, I will bet it is below 300M or maybe below 200M range. A good measure is when you see a stock moves 100% in one-day (not the trips though) with whatever the volume is, the float is likely around that number. In other words, a general rule of thumb is a $1 stock will become $2 when the entire float churns. That is not valid for trips, however.

2) For SPCL most people like myself are holding for long-term, so the real available float id getting smaller every day.

3) Then you have traders
who are buying and selling, taking their investment out and holding what they call the "free shares
" for the long haul. They are carrying no risk at this point as they got the investment out. My guess is as the pps keeps moving up this crowd will get more and more making the available float even smaller.

4) So the pps will move up much faster once it reaches $0.05 range

5) The company is doing a RS with clear intent for uplisting. The oS after the RS will be a tiny 18M and the float maybe 2-3 M shares
. After the RS and uplisting the stock will sky rocket and I for one to plan to hold it for very long time. I am hoping that it will become a long-term investment. That is my goal.

6) Ignore the revenue and don't even try to do XPEG multiple. Private companies which are Silicon Valley VC backed gets 100x-500x revenue valuation. Revenue right now is irrelevant.

7) What is relevant is their PROJECTED growth rate. That will be the key piece of information one has to look out for when it comes out after or during the Uplisting.

8) They are the market leader in this space now which is another key point for valuation. That's why Uber is > $65 Billion valuation now.

9) My guess is with 18M OS after the RS and Uplisting if they can get say $900M valuation, that will be put the pre-split pps of $0.50, 35X from here

10) I am thinking that is their goal. If they get $1B-$2B valuation, then at that point they can do a secondary and raise $200-$300M easy say at $100 a piece.

These are all my assumption as I work with Startups, and Fund raising on a daily basis. I am assuming that these are a bunch of serious professionals with high level of ethics NOT some pinky scammers. All things points to the fact that they are serious and trying to do it right.

Good Luck with whatever you do
Respond | No replies

Solaris Power Cells, Inc (SPCL) Stock Research Links

SPCL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Melrose Fire Station Reaches Steel Topping Milestone

Updated Category News Views 3

Metal and Milestones: A New Era for Melrose Rolling into Melrose, Massachusetts, there's some serious action kicking off with the new Fire Engine 2 Station reaching a steel topping milestone. This phase isn't just about slapping on another beam; it's the crescendo of diligent teamwork from all the hands involved—from CTA Construction Managers to the clout of Ironworkers...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading

Top 5 Most Recently Viewed Articles

SBVA Triumphs as Venture Capital Leader in Prestigious Award

Updated Category News Views 194

SBVA Achieves Prestigious Recognition SBVA, formerly known as SoftBank Ventures Asia, recently earned the esteemed title of "VC of the Year" at the annual Korea Venture Capital Awards. This significant honor highlights SBVA's remarkable investment performances and its vital role in enhancing the venture ecosystem. The Importance of the Korea Venture Capital Awards The...

Continue Reading
Strategic Acquisition: TopBuild Expands with Metro Supply Company

Updated Category News Views 116

Strategic Acquisition by TopBuild TopBuild Corp. (NYSE:BLD), a leader in insulation installation and specialty distribution for the construction sector, has recently made a significant move by agreeing to acquire Metro Supply Company. This acquisition is set to enhance TopBuild’s offerings in the commercial and industrial insulation market and is expected to bring in...

Continue Reading
Key Class Action Update on MoonLake Immunotherapeutics (MLTX)

Updated Category News Views 117

MoonLake Immunotherapeutics Faces Class Action Lawsuit Investors should be aware that MoonLake Immunotherapeutics (NASDAQ: MLTX) is currently facing a class action lawsuit due to alleged violations of securities laws. The DJS Law Group is actively reminding shareholders of their rights in light of this legal action, emphasizing the importance of staying informed during...

Continue Reading
Columbus McKinnon Set to Shine at Global Industrial Conference

Updated Category News Views 119

Columbus McKinnon Corporation's Participation in a Key Event Columbus McKinnon Corporation (Nasdaq: CMCO), a prominent name in the design and manufacturing of motion solutions, is excited to announce its participation in an upcoming event that is significant for the industry. The company will showcase its expertise at the Baird Global Industrial Conference. This important...

Continue Reading
The Growth of a $100 Investment in Norfolk Southern Over 20 Years

Updated Category News Views 64

The Benefits of Long-Term Investments in Norfolk Southern Investing wisely can truly change your financial landscape, and Norfolk Southern (NYSE: NSC) is a stellar example of this. Over the last 20 years, investing in NSC has yielded remarkable results, achieving an annualized growth rate of 5.31%. This outstanding performance has led to an impressive average annual...

Continue Reading